Home » Newsletters » BioWorld Science

BioWorld Science

March 1, 2012

View Archived Issues

BMS and Duke Translational Medicine Institute broaden their collaboration

Researchers identify biomarker for ulcer-type interstitial cystitis

Potassium channel blocker has antiobesity effects in animal models

Collaborating Australian universities design new candidate schizophrenia therapies

New marker and potential therapeutic target identified for castration-resistant prostate cancer

AVI BioPharma clear to proceed with studies of AVI-6003 component

Merck & Co. designs new products with potential to treat hepatitis C

Amgen divulges novel beta-secretase 1 inhibitors

Novel ALK inhibitors created with anticancer potential

Merck KGaA reports new P70S6K inhibitors

Novel protease-activated PAR2 receptor ligands developed in Australia

New protein kinase inhibitors identified at Nerviano Medical Sciences

Dainippon Sumitomo Pharma reaches agreement on acquisition

OncoTherapy Science updates on cancer peptide vaccine pipeline

BCI-838 enters new phase I trial

Shire and arGEN-X to develop therapeutic antibodies for rare diseases

Creabilis begins phase IIb CT-327 study

Biotie completes PET imaging study of serotonin 5-HT6 receptor antagonist

Essentialis reports results from phase IIb trial of DCCR

Baxter International begins study of stem cell therapy for chronic myocardial ischemia

FDA accepts Tau Therapeutics' IND for repositioned drug

Johns Hopkins and ImmunoCellular Therapeutics enter licensing agreement for cancer antigen

Polaris begins dosing in study of cancer therapy in pediatric patients

Global rights to biocrea phosphodiesterase program transferred

FDA grants orphan drug status to treatment for lysosomal storage disorder

Avanir and Concert Pharmaceuticals to develop deuterium-modified dextromethorphan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 24, 2026.
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026